Skip to content

RANDOMIZED AND CONTROLLED THERAPEUTICAL ASSAY OF THE VERRUCOSE PHASE OF INFECTION BY BARTONELLA BACILLIFORMIS IN PERU.

RANDOMIZED AND CONTROLLED THERAPEUTICAL ASSAY OF THE VERRUCOSE PHASE OF INFECTION BY BARTONELLA BACILLIFORMIS IN PERU.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-085-02
Enrollment
128
Registered
2002-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Azithromycin Type of group
Azithromycin will be administered weekly once for two weeks (it provides effective tissue levels for two weeks)
adults will receive 1.0 gram orally on days O and 8
Rifampicin Type of group
Rifampicin will be administered at the following doses for two weeks
adults will receive 600mg orally daily
children will receive 10mg / kg daily (without exceeding 600mg orally per day).

Sponsors

UNIDAD TERRITORIAL DE SALUD CARAZ,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age: 1-60 years Clinical diagnosis Able to give informed consent Without exclusion criteria Stay in the area for 2 months

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Oral contraceptives Chronic alcohol consumption Liver disease Medicines that interact Admission to the hospital for an unrelated cause Use of antibiotics in the previous 30 days

Design outcomes

Primary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated

Secondary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated

Countries

Peru

Outcome results

None listed

Source: REPEC (via WHO ICTRP)